Novartis and Incyte to trial Jakavi for Covid-19
Novartis, in alliance with Incyte, has announced plans to assess Jakavi (ruxolitinib) in a Phase...
Vertex-Semma $950m acquisition: bringing diabetes into the pipeline
Vertex Pharmaceutics has announced it has entered into a definitive agreement to acquire Semma Therapeutics...
Maze Therapeutics raises $191m to support genetic research
Third Rock Ventures has launched Maze Therapeutics, a start-up focused on translating genetic insights into new medicines.
GE to divest its Biopharma business to Danaher for $21.4bn
US-based conglomerate General Electric (GE) has entered into a definitive agreement to divest its Biopharma...
Outcome-based payment system could expedite cancer treatment
A new report by Cancer Research UK has concluded that a new drug payment system,...
FDA agrees to review AbbVie’s upadacitinib in rheumatoid arthritis
The US Food and Drug Administration (FDA) has accepted a new drug application (NDA) submitted...
No-deal Brexit could put UK patients at risk of fake medicines
The Association of the British Pharmaceutical Industry (ABPI), a trade group representing drugmakers in the...
Taiho Pharmaceutical licences lung cancer drug to Cullinan Oncology
Japan-based Taiho Pharmaceutical has signed an agreement to licence its epidermal growth factor receptor (EGFR)...
US Government’s new rule targets drug industry’s rebate system
US Department of Health & Human Services (HHS) has proposed a new rule to end...
UK unveils plan to tackle growing antimicrobial resistance
The UK Government has set out a plan to fight antimicrobial resistance (AMR) in the...